The Osgood-Schlatter market is expected to reach USD 3,554.27 Million by 2030, and the market is projected to grow at a CAGR of ~ 4.10% during the forecast period 2022-2030.
Osgood–Schlatter disease (OSD), is the inflammation of area below the knee characterized by a painful bump just below the knee which worsens with activity. OSD typically affects growing adolescents during puberty and is common in those participating in sports and other physical activities. OSD causes a painful lump below the kneecap, resulting in swelling and tenderness affecting the knee. Risk factors include high intensity sports such as running or jumping.
OSD generally resolves with time especially with rest. OSD affects 4% of people at least once in their lifetime and is more common in males between the ages of 10 and 15. The male to female ratio is approximately 5:1.
The symptoms of OSD includes knee pain, swelling, tenderness, increased warmth under the knee and others. In extreme cases OSD may result in fracture.
The market drivers for Osgood-Schlatter market are rise in population, increasing awareness and screening, development of healthcare and orthopaedic centres, rise in sports culture, growth of physiotherapy and advancements in drugs and surgery etc. The market restraints are the complications of treatment such as pain, bleeding, high cost of treatment, competition from alternative treatment and self-correcting nature of the disease etc.
Sources: Mayo Clinic, Healthline Media, MRFR Analysis
The Osgood-Schlatter market has been segmented on the basis of diagnosis, treatment and end user.
Based on the diagnosis, the Osgood-Schlatter market has been segmented as physical examination, ultrasonography, X-ray, combination, and other.
Based on the treatment, the Osgood-Schlatter market has been segmented as non-steroidal anti-inflammatory drugs, physical therapy, knee braces and supports, surgery, and others.
Based on the end user, the Osgood-Schlatter market has been segmented as hospitals & clinics, academic and research, and others.
The Americas account for a significant market share owing to high expenditure on the health care. Additionally, the fastest uptake of new healthcare products in the US drives the Osgood-Schlatter market. Furthermore, concentration of the major healthcare companies and hospitals in the developed countries of this region coupled with large insurance penetration is adding fuel to the market growth. Moreover, the US expend high amount on its healthcare, which accounts for 16% of total GDP, which also increases the sale in Osgood-Schlatter market.
Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period. The strong pharmaceutical industry in Germany is a strong driver behind the dominance of this country in Europe.
The large sporting culture and popularity of sports and media influence in the developed regions is expected to drive the future market.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future Osgood-Schlatter market in the region.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt, and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.
Key Players in the Global Osgood-Schlatter Market
Some of the key players profiled in the Osgood-Schlatter market report are DJO Global, Inc., Teva Pharmaceutical Industries Ltd., Breg, Inc., Bayer HealthCare Pharmaceuticals LLC, Ossur HF, Daiichi Sankyo Company, Limited, Pfizer, Inc., Novartis AG, and others.
|Market Size||2030: USD 3,554.27 Million|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Diagnosis, Treatment and End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||DJO Global, Inc., Teva Pharmaceutical Industries Ltd., Breg, Inc., Bayer HealthCare Pharmaceuticals LLC, Ossur HF, Daiichi Sankyo Company, Limited, Pfizer, Inc., Novartis AG, and others|
|Key Market Opportunities||New product launches and R&D Amongst major key Players|
|Key Market Drivers||